We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: orth America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Therapeutic indications
indicated for the treatment of neuropathic pain in adults .and It is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
Dose and method of administration
The dose range is 150 to 600 mg per day given in two divided doses.may be taken with or without food.
Neuropathic Pain
treatment can be started at a dose of 150 mg per day, given as two divided doses. Based on individual patient response and tolerability, the dosage may be increased to 300 mg per day, given as two divided doses, after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.
Epilepsy treatment can be started with a dose of 150 mg per day given as two divided doses. Based on individual patient response and tolerability, the dosage may be increased to 300 mg per day given as two divided doses after 1 week. The maximum dosage of 600 mg per day given as two divided doses may be achieved after an additional week.
Hepatic Impairment
No dosage adjustment is required for patients with hepatic impairment
Children and Adolescents (<18 years)
The safety and effectiveness of pregabalin has not been established in patients below the age of 18 years, with either epilepsy or neuropathic pain.
Elderly (>65 years)
No dosage adjustment is necessary for elderly patients unless their renal function is
compromised
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
